Cargando…

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

BACKGROUND: Despite the introduction of several novel therapeutic approaches that improved survival, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Herein we report the synergistic antitumor interaction between two well-known drugs used for years in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iannelli, Federica, Roca, Maria Serena, Lombardi, Rita, Ciardiello, Chiara, Grumetti, Laura, De Rienzo, Simona, Moccia, Tania, Vitagliano, Carlo, Sorice, Angela, Costantini, Susan, Milone, Maria Rita, Pucci, Biagio, Leone, Alessandra, Di Gennaro, Elena, Mancini, Rita, Ciliberto, Gennaro, Bruzzese, Francesca, Budillon, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545949/ https://www.ncbi.nlm.nih.gov/pubmed/33032653 http://dx.doi.org/10.1186/s13046-020-01723-7

Ejemplares similares

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
por: Milone, Maria Rita, et al.
Publicado: (2014)

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
por: Lombardi, Rita, et al.
Publicado: (2021)

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
por: Ciardiello, Chiara, et al.
Publicado: (2019)

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid
por: Bizzarro, Valentina, et al.
Publicado: (2015)

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
por: Bruzzese, F, et al.
Publicado: (2013)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2013)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2014)

An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer
por: Costantini, Susan, et al.
Publicado: (2022)

The emerging role of cancer cell plasticity and cell-cycle quiescence in immune escape
por: Bruschini, Sara, et al.
Publicado: (2020)

Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

Drug repurposing against COVID-19: focus on anticancer agents
por: Ciliberto, Gennaro, et al.
Publicado: (2020)

Cancer stem cells (CSCs), cervical CSCs and targeted therapies
por: Huang, Ruixia, et al.
Publicado: (2016)

Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles
por: Sorice, Angela, et al.
Publicado: (2016)

Pancreatic CSCs and microenvironment
por: Ilmer, Matthias, et al.
Publicado: (2015)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
por: Roca, Maria Serena, et al.
Publicado: (2019)

The promise of anti-ErbB3 monoclonals as new cancer therapeutics
por: Aurisicchio, Luigi, et al.
Publicado: (2012)

ATLAS computing on CSCS HPC
por: Filipcic, Andrej, et al.
Publicado: (2015)

ATLAS computing on CSCS HPC
por: Hostettler, Michael Artur, et al.
Publicado: (2015)

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
por: Fattore, Luigi, et al.
Publicado: (2019)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays
por: Capone, Francesca, et al.
Publicado: (2016)

CSCs: regenerating optimism for osteosarcoma treatment
por: Levin, Adam S.
Publicado: (2018)

ALDH1A3 in CSCs
por: Sullivan, Kelly E., et al.
Publicado: (2017)

Eradication of CSCs: the roadmap for curing cancer
por: Romano, Simona, et al.
Publicado: (2020)

Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers
por: Polo, Andrea, et al.
Publicado: (2018)

CSCs in Breast Cancer—One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs
por: Sulaiman, Andrew, et al.
Publicado: (2019)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Thrombotic microangiopathy associated with Valproic acid toxicity
por: Hebert, Sean A., et al.
Publicado: (2017)

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial)
por: Avallone, Antonio, et al.
Publicado: (2014)

SCD1, autophagy and cancer: implications for therapy
por: Ascenzi, Francesca, et al.
Publicado: (2021)

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol
por: Avallone, Antonio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tcac00l17rbkpr2csbe139t4i6